Atezolizumab and bevacizumab for hepatocellular carcinoma: how to approach salvage therapy for non-responders?

Clin Mol Hepatol. 2024 May 7. doi: 10.3350/cmh.2024.0324. Online ahead of print.

Author

Naoshi Nishida¹

Affiliation

¹ Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi Osaka-Sayama, 589-8511, Japan.

PMID: 38711304
DOI: 10.3350/cmh.2024.0324

No abstract available

Publication types

Editorial